NCT04456920 2025-12-02
BIO-PSY
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
Clinical Trials
6 trialsNCT05258747 2024-10-03
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Sandoz
Phase 1 Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT05840068 2023-05-03
IGF Level in Breast Cancer Patients Treated With Metformin
Beni-Suef University
Phase 4 Completed
NCT04434404 2020-06-16
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
Horus University
Phase 4 Completed
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed